After lengthy negotiations, Bayer has reached a deal with union representatives that will result in a sizeable reduction in managerial roles, part of a cost-cutting drive
One of Germany’s main trade unions has pushed back against any future break-up of pharmaceutical and agrochemicals giant Bayer, claiming such a move would put thousands of
Aclaris Therapeutics has said it will cut 46% of its workforce after deciding to discontinue the development of lead drug zunsemetinib (ATI-450) for immuno-inflammatory in
Pfizer has fleshed out some more of the details of its wide-ranging cost-cutting drive announced last month, revealing that around 500 jobs will go in the UK, including at
Bayer’s new chief executive Bill Anderson has launched a “re-design” of Bayer that will see layers of management stripped out by the end of next year, with “95% of the dec
A positive clinical trial is usually a signal for a biotech startup to press the accelerator on its spending, but Kronos Bio is taking a different tack.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS